SCTX (Scribe Therapeutics) Ending Cash Position: $21.06 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCTX Scribe Therapeutics Inc SCTX
8 GF Score
Price $22.00
View Full Analysis

What is Scribe Therapeutics Ending Cash Position?

Scribe Therapeutics SCTX -13.40% 8 Ending Cash Position is $21.06 Mil as of Mar. 2026. GuruFocus rates SCTX with a GF Score™ of 8/100.

Scribe Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was $21.06 Mil.

Scribe Therapeutics's quarterly Ending Cash Position declined from Mar. 2025 ($20.57 Mil) to Dec. 2025 ($0.00 Mil) but then increased from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($21.06 Mil).

Scribe Therapeutics's annual Ending Cash Position increased from . 20 ($0.00 Mil) to Dec. 2024 ($13.28 Mil) and increased from Dec. 2024 ($13.28 Mil) to Dec. 2025 ($13.47 Mil).

Scribe Therapeutics Ending Cash Position Related Terms

Scribe Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Scribe Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scribe Therapeutics Ending Cash Position Chart

Scribe Therapeutics Annual Data
Trend Dec24 Dec25
Ending Cash Position
13.28 13.47

Scribe Therapeutics Quarterly Data
Dec24 Mar25 Dec25 Mar26
Ending Cash Position 0.00 20.57 0.00 21.06
SCTX
8GF Score
Scribe Therapeutics Inc SCTX
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scribe Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Scribe Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=13.277+0.194
=13.47

Scribe Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=13.471+7.585
=21.06

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $21.06 Mil mean?
Scribe Therapeutics (SCTX) has a Ending Cash Position of $21.06 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Scribe Therapeutics and its competitors.
Is Scribe Therapeutics' Ending Cash Position too high?
Scribe Therapeutics' current Ending Cash Position is $21.06 Mil. Overall, Scribe Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Scribe Therapeutics' Ending Cash Position compare to ?
Scribe Therapeutics' Ending Cash Position of $21.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Scribe Therapeutics and its competitors. Scribe Therapeutics's current Ending Cash Position is $21.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scribe Therapeutics stock overvalued right now?
Scribe Therapeutics (SCTX) has a current Ending Cash Position of $21.06 Mil. The current Ending Cash Position is $21.06 Mil. Scribe Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Scribe Therapeutics (SCTX), the current Ending Cash Position is $21.06 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scribe Therapeutics Business Description

Comparable Companies
Address 1150 Marina Village Parkway, Alameda, CA, USA, 94501
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
8GF Score

Get the complete analysis for SCTX

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.00
Price